Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer

Table 2 The responses of 40 Chinese patients with mCRC to the SOL regimen

SOL the combination of S-1, oxaliplatin, and leucovorin regimen. Other abbreviation as in Table 1
^a95% confidence interval of overall response rate is 33.8%–66.2%

ISSN: 2523-3548